Publications

View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.

December 2022

Deucravacitinib in Moderate-to-severe Psoriasis

Immunotherapy. 2022 doi: 10.2217/imt-2022-0109

Vu A,

Maloney V,

Gordon KB

Deucravacitinib demonstrates promising results as a TYK2-specific immunotherapy and shows considerable efficacy yet is able to avoid the side effect profile observed with other JAK inhibitors.

Keywords:

TYK2,
Deucravacitinib,
Review